Sergij Goerdt

Sir, The tyrosine kinase inhibitor imatinib (Glivec, formerly STI571; Novartis, Basel, Switzerland) selectively impairs the function of the platelet‐derived growth factor receptor and c‐kit (CD117). Moreover, imatinib inhibits the BCR‐ABL f…